Search results
Results From The WOW.Com Content Network
US$1.04 billion (2022) [1] Number of employees. 2,100 (2023) [2] Website. alnylam .com. Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is ...
Alnylam Pharmaceuticals Reports Second Quarter 2013 Financial Results - Reported Positive Clinical Data from Two "Alnylam 5x15" Programs: ALN-TTR02 for the Treatment of Transthyretin (TTR ...
About Alnylam Pharmaceuticals. ... (SEC) on May 7, 2013 and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today ...
About Alnylam Pharmaceuticals. Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. ... 2013 and in other filings that Alnylam makes with the ...
Alnylam Pharmaceuticals Reports Fourth ... A corporate slide presentation will also be available on the News & Investors page of ... (SEC) on January 14, 2013 and in other filings that Alnylam ...
By Mariam Sunny (Reuters) -Alnylam Pharmaceuticals said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug ...
What: Shares of biotechnology firm Alnylam. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
What: Shares of Alnylam Pharmaceuticals , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...